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Enteric fevers continue to cause considerable morbidity and mortality in
nations that have not yet achieved control of drinking water and sewage disposal
(1, 2). In these countries, the most frequent and serious cause of enteric fevers
is Salmonella typhi (typhoid fever) (2). Immunoprophylaxis against typhoid fever
on a world-wide basis has not been attempted because the two available vaccines
have limitations; (a) cellular typhoid vaccines induce only a limited immunity
and elicit side reactions that are frequent and severe enough to have discouraged
their widespread acceptance (2, 3); and (b) an orally administered attenuated
strain of S. typhi, Ty-21a, requires three to four doses to induce about 65%
protection, it is expensive, and its mode of protection has not been identified,
which has prevented precise standardization of the vaccine (1, 4).
Recently, two clinical evaluations in populations with high rates of typhoid
fever (-..1%/annum) have provided evidence that immunization with the capsular
polysaccharide (CPS)' ofS. typhi (Vi) confers immunity against typhoid fever (5,
6). The Vi vaccine, prepared under conditions that did not change its structure,
elicited a fourfold or greater rise in serum antibodies in -75% ofchildren and
adults in Nepal and in school children in the Eastern Transvaal, Republic of
South Africa (2, 7, 8). The protective efficacy of the Vi in these two trials was
^-70%. In contrast, the same Vi elicited a _>4-fold antibody rise in 97% of young
adults in France and the United States (9). The seroconversion rate and efficacy
of other CPS, e.g., meningococcal vaccines, were also lower in Africa than in
Finland or the United States (10-12). This lesser immunogenicity and efficacy
of meningococcal vaccines was attributed to the high burden of infections,
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' Abbreviations used in this paper:
￿
Vi, Vi capsular polysaccharide; CPS, capsular polysaccharide;
SPDP,N-succinimidyl 3-(-2-pyridyldithio) propionate; EDAC, 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide; TT, tetanus toxoid; DT, diphtheria toxoid; CT, cholera toxin; RIA, radioimmunoassay;
NMR, nuclear magnetic resonance; FTIR, Fourier-transformed infrared spectroscopy.
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including malaria, in the African population. Since the protective response
elicited by CPS vaccines is serum antibodies, it could be predicted that a more
immunogenic Vi would be more protective against typhoid fever in high-risk
populations.
Originally, Goebel and Avery (13, 14) showed that the immunogenicity of
pneumococcus type 3 polysaccharide could be increased by binding it chemically
to a carrier protein. This principle has been applied successfully to increase the
immunogenicity of CPS of other pathogens (15-23). We developed methods for
synthesizing covalent bonds between the Vi and proteins to both increase the
immunogenicity of and to confer the property of T-dependence to this antigen .
Vi, a linear homopolymer of -4-D-a-NAcGalA-(1- is O-acetylated up to 90% at
C3 (24). The scheme used to prepare these conjugates used the carboxyl function
of the NacGalA to form a thiol derivative. This thiol derivative was combined
with proteins derivatized by the thiol-active compound, N-succinimidyl-3-(2-
pyridyldithio) propionate (SPDP) (25). The standardization and immunologic
properties of several model Vi-protein conjugates formed by this method are
reported here .
Materials and Methods
Vi CPS (Vi).
￿
The Vi used for the conjugates was prepared from Citrobacterfreundii,
strain WR 7011, kindly given to us by Dr. Lewis Baron, Walter Reed Army Institute of
Research, Washington, DC. C. freundii was cultivated in medium containing yeast extract
dialysate as described (3). Vi was precipitated from the culture supernatant with 1%
hexadecyltrimethyl ammonium bromide (Sigma Chemical Co., St. Louis, MO) and se-
quentially treated with DNase, RNase, and then pronase (19, 27, 28). The enzyme-treated
product was purified with cold phenol and the LPS was removed by centrifugation at
60,000 g, 10 0'C, for 5 h (10). The Vi was dialyzed exhaustively against pyrogen-free water
and freeze-dried. Vi from S. typhi was prepared by a modification of this method by the
Institut Merieux, Lyon, France (9). The final products contained <1% protein or nucleic
acid (26) and <0.01 % LPS as measured by SDS-PAGE (29). The molecular size of the Vi
preparations was heterogeneous; the main peak had a molecular mass 5 x 10s kD as
estimated by gel filtration through Sephacryl S-1000 (Pharmacia Fine Chemicals, Pisca-
taway, NJ) equilibrated in 0.2 M NaCl. A lower molecular size Vi, ^- 65 kD was prepared
by ultrasonic irradiation (30).
Proteins.
￿
BSA (Sigma Chemical Co.) and cholera toxin (CT, Lot 582; Institut Merieux)
were used without further purification. Tetanus toxoid (TT; Institut Merieux) and
diphtheria toxoid (DT; Rijks Instituut voor Volksgezonheid, Bilthoven, Netherlands) were
further purified by gel filtration through Sephacryl S-300 (Pharmacia Fine Chemicals)
equilibrated in 0.2 M NaCl (17, 22). The fractions,corresponding to the molecular weight
of the two toxoids, were concentrated by ultrafiltration and passed through 0.45-/m
filters (Millipore Co., Bedford, MA). CT was additionally characterized for toxicity by the
Chinese hamster ovary (CHO) cell assay and by the intradermal rabbit skin test (kindly
performed by Dr. John Craig, State University of New York, Brooklyn, NY) (31).
Direct Binding ofVi to Proteins with EDAC (Vi-DT,).
￿
Vi was bound to DT by the method
of Beuvery et al. (16). Equal volumes of Vi and DT, containing 10 mg/ml each, were
mixed, the pH was adjusted to 5 .0 with 0.1 N HCI, and 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDAC) (Bio-Rad Laboratories, Richmond, CA) was added to a final con-
centration of 0.1 M . The pH was maintained at 5.0 by addition of 0.1 N HCI for 3 h at
room temperature. The reaction mixture was stirred at 3-8°C for an additional 24 h,
dialyzed against 0.2 M NaCl for 48 h, and then centrifuged at 10,000 g, for 2 h, at 3-
8°C. The supernatant fluid was subjected to gel filtration through 4B-Sepharose equili-
brated in 0.2 M NaCl . The fractions were monitored by refractometry and by absorption1512
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at 2,800 A. The void-volume fractions, which contained the Vi-DT, conjugate, were
pooled, made 0.01 % in thimerosal (Eli Lilly and Co., Indianapolis, IN), and stored at 3-
8°C.
Thiolation of Vi with Cystamine.
￿
Vi, 10 mg/ml in 0 .2 M NaCl, was allowed to dissolve
overnight at 3-8°C. Cystamine or cysteamine (Calbiochem-Behring Corp., La Jolla, CA)
at twice the weight of the Vi was then added as a powder to the Vi solution. The pH of
the reaction mixture was adjusted to 4.9 with 0.1 N HCl and the temperature was
maintained at 37° C. EDAC, in an amount equal to the weight of the Vi, was added to
the reaction mixture with stirring. The pH was maintained at about 4.9 by the addition
of 0.1 N HCl until stable. The reaction mixture was then dialyzed exhaustively against
distilled water at 3-8'C and freeze-dried. The extent of thiolation was estimated by the
iodoplatinate assay (32) using cystamine as the reference. The thiol ester content was
quantitated after reduction of the Vi derivative with DTT (Sigma Chemical Co.) and
passage of the reaction mixture through Bio-Gel P10 (Bio-Rad Laboratories) to remove
the low molecular weight materials. The material eluted in the void volume was then
assayed for its SH content using cysteamine as a standard (33).
Derivatization ofProteins with SPDP.
￿
Protein solutions were made within a range of 5-
20 mg/ml. Free SH groups were blocked by treatment with 0.01 M iodoacetic acid (Sigma
Chemical Co.). The reaction mixture, containing the iodoacetic acid and the protein, was
incubated at room temperature for 1 h and then equilibrated against 0.15 M Hepes
(Boehringer Mannheim Biochemicals, Indianapolis, IN), 5 mM EDTA, pH 7.55 (HE
buffer) by dialysis overnight at 3-8°C. SPDP (Pierce Chemical Co., Rockford, IL), 20
mM in 99.5% ethanol, was added to the protein solution with stirring (25). The final
molar ratio of SPDP to protein ranged from 5-25 depending upon the extent of
derivatization desired. The reaction was allowed to proceed for 1 h at room temperature.
The excess reagent was removed by dialysis against HE buffer overnight at 3-8 °C followed
by gel filtration through Bio-Gel P10 in HE buffer. The void volume was pooled,
concentrated to 5-10 mg/ml, and stored at 3-8'C. The molar ratios of 2-pyridyl
disulphide in the derivatized protein were determined by reducing the disulfide bond in
50 mM DTT and calculating the amount of pyridine-2-thione released by using the
extinction coefficient for pyridine of 8 .08 x 10s/mot/cm at 3,430 A (23, 25).
Synthesis of Vi-Protein Conjugates.
￿
The cystamine derivative of Vi was dissolved in HE
buffer, at 5-10 mg/ml. DTT was added to a final concentration of 100 mM and stirred
for I h at room temperature. Afterdialysis against HE buffer for 2 h, the reaction mixture
was then passed through a Bio-Gel P10 column, equilibrated with HE buffer and the void
volume peak was concentrated by ultrafiltration (Amicon Corp., Danvers, MA; molecular
weight cutoff >5,000) under N2 pressure. SPDP-derivatized protein was added to the
reduced Vi derivative to achieve an equimolar ratio ofN-pyridyl disulfide groups and SH
groups. The reaction mixture was flushed with N2 and allowed to incubate at room
temperature for 1 h, and then at 3-8°C for 24 h. The release of pyridine during the
reaction was measured by the change in OD 3,430 A. The reaction mixture was concen-
trated by ultrafiltration (see above) and subjected to gel filtration through Sephacryl 5-
1000 in 0.2 M NaCl at room temperature. The void volume fractions were pooled,
concentrated by ultrafiltration, dialyzed against 0.15 M NaCl, 0.01 % thimerosal (Eli Lily
and Co .), I mM EDTA, pH 7.0, and stored at 3-8 °C. The protein concentration of the
conjugate was determined by the Coomassie Blue assay (Bio-Rad Laboratories) using the
SPDP-derivatized protein as the standard (34). The concentration of protein and Vi in
the conjugates were also determined by Fourier transformed infrared spectroscopy (FTIR)
and by spectrophotometric titration by acridine orange (35).
Pneumococcus Type 6B-TTConjugate (Pn6B-TT).
￿
Pneumococcus type 6B CPS, (Institut
Merieux), was derivatized with adipic acid dihydrazide and bound to TT as described (17,
20, 22). The protein/polysaccharide ratio of this preparation was 2.8 .
Immunization of Mice.
￿
Female, weanling, BALB/c mice, 16-20 g, were injected sub-
cutaneously with 0.1 ml of either Vi, Vi conjugates or saline 1, 2, or 3 times at 2 wk apart.
Mice from each experimental group were exsanguinated 10 d after each injection. Alum-
adsorbed Vi-CTX was prepared with Alhydrogel (Superfos; Kemi A/S, Copenhagen,SZU ET AL.
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Denmark). The Alhydrogel was centrifuged and Vi-CTxu was added to the pellet to
achieve a final concentration of 0.5 mg aluminium/ml and 5 .0 Kg of Vi as a suspension.
This mixture was tumbled overnight at room temperature and then stored at 3-8°C.
Immunization ofPrimates.
￿
Juvenile Rhesus monkeys, housed at the Division of Product
Quality Control, Office of Biologics Research and Review, FDA, were injected subcuta-
neously twice, 1-mo apart with 0.5 ml of Vi or Vi-CTx,i containing 25 kg of Vi. Controls
were injected with Pn6B-TT containing 15 ttg of CPS (20). The monkeys were bled
before and 3 wk after each injection.
Immunological Methods.
￿
Serum Vi antibodies were measured by RIA and expressed as
,ug antibody/ml (9). The differences between the levels of antibodies in experimental
groups were calculated by Fisher's exact t-test. The results were tabulated as the geometric
mean and 80% confidence limits. Antibodiesto CT were measured by ELISA (36). Rabbit
anti-BSA serum was obtained from Cappel Laboratories, Cochranville, PA. Hyperimmune
burro antiserum, (B-260) containing 660 Ag Vi antibody/ml, was prepared by multiple
intravenous injections of formalin-fixed S. typhi Ty2 as described (37). The preparation
and characterization of burro 241, hyperimmune CT antiserum, containing 16 .5 mg
antibody/ml, has been reported (38). Rocket immunoelectrophoresis and immunodiffu-
sion were performed as described (23).
FTIR Spectroscopy.
￿
The composition of the conjugates was determined using the Vi
and proteins as references. 1 mg of Vi, carrier protein, or Vi conjugate was added to 100
mg of KBr, and dissolved in 2.0 ml distilled water. The sample was freeze-dried and
pressed into a pellet. FTIR spectra were recorded on a Nicolet 7199 spectrometer and
analyzed as described (35).
f "CJNuclear Magnetic Resonance (NMR).
￿
['gC]NMR spectra ofthe Vi (20 mg/ml D20)
were recorded at 60°C in a Nicolet 270 spectrometer. A 5 .0-mm sample cell was used
and the spectrometer was operated at 67.9 MHz in the pulse Fourier-transformed mode
with complete proton decoupling and quadrature phase detection. A 4-Hz line broadening
was applied to the signal before Fourier transformation to enhance the signal-to-noise
ratio.
SDS-PAGE. The molecular weights of the proteins and their Vi conjugates were
assayed in 7.5% polyacrylamide gels (23). Samples containing 5-10 ug of protein with or
without 2-ME were electrophoresed concurrently with protein standards (Pharmacia Fine
Chemicals). The gels were stained with Coomassie Blue (Sigma Chemical Co.).
Results
Vi Antigens.
￿
The Vi from S. typhi and some strains of C. freundii is a linear
homopolymer of NacGaIA acid, variably O-acetylated at the C3 position (24).
FTIR and [ 1sC]NMR spectroscopy showed that the structures of the Vi from the
WR 7011 strain of C.freundii and the Ty2 strain ofS. typhi were indistinguishable
(39, 40) (Fig. 1). Immunodiffusion analyses showed a reaction of identity between
Vi polysaccharides from C. freundii and S. typhi when reacted with B-260 anti-Vi
antiserum (data not shown). The Vi used for immunization and for synthesis of
the conjugates in these experiments contained about 80% 0-acetyl per mole
repeating unit as determined by [' 3C]NMR (Fig. 2). Since the Vi has no vicinal
hydroxyl groups, the carboxyl served as an activation site in the strategy for the
conjugation reaction .
Direct Binding of Vi with Proteins Using EDAC.
￿
The first Vi conjugates were
prepared with EDAC, which catalyzed the direct conjugation between the
carboxyls of Vi and the amino groups of DT (16). The yield from this reaction,
illustrated by a representative product Vi-DTI, was ^-3% ofthe starting materials.
Vi antibody levels elicited in mice by this conjugate and by the two controls, Vi
and saline, are given in Table I.1514
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OAc
- 4)-a-D-Gal NAc A-(1 --
b
￿
c
HIS -(CH2)= -NH2
￿
2HN-(CH2)2 -S-S-(CH2)2 -NHZ
cysteamine cystamine
TABLE I
Serum Antibody Responses ofFemale BALE/c Mice Injected with Vi or Vi-DT Conjugate (Vi-
DTI)Prepared with EDAC as the coupling reagent
FIGURE 1 .
￿
(a) Structure of the repeating unit of
the Vi capsular polysaccharide of Salmonella typhi.
(b) Structure of cysteamine. (c) Structure of cys-
tamine.
r
0 PPM
FIGURE 2. ['"CJNMR chemical
shift of Vi depolymerized by ul-
trasonic irradiation (65,000 mol
wt, 20 mg/ml concentration),
downfield from "C-enriched ac-
etonitrile used as an internal stan-
dard. The spectra were recorded
fora D20solution in a5-mm tube
with a Nicolet 270 spectrometer
operating at 67.89 MHz in pulse
Fourier-transformed mode.
Mice were injected subcutaneously 2 wk apart with 0.1 ml of each vaccine or saline. There were
eight mice for each experimental group. 10 d after each injection mice were exsanguinated and
their sera were assayed forVi antibodies by RIA (9). Results are expressedas the geometric mean
and 80% confidence limits.
vs. ** : p = 0.0014, ** vs. tt, III: P = 0.001, ovs. "I, $ vs. H: P = 0.001, 1 vs.
￿
vs. ***: P = 0.0001,
# vs, ff: P = 0.003.
There were no Vi antibodies in preimmune sera or from mice injected with
saline (controls) in this and subsequent experiments. Dosages of 0.5, 5.0, or 50.0
ug of Vi elicited similar levels of antibodies after the first, second, and third
injections; the slightly higher levels of antibodies in the group injected with 5.0
Ag of Vi after the third injection were not statistically different. The levels of
antibodies after the second and third injections of 5.0 or 50.0 Ag of Vi-DTI were
Vaccine Dose
1st
Vi antibody
2nd 3rd
wg uglml ug/ml Ag/ml
Vi 0.5 0.19* (0.05-0.72) 0.61 (0.30-1.23) 0.47 (0.19-1.15)
5.0 0.56 (0.28-1.11) 0.431 (0.13-2.33) 1.11 (0.29-4.26)
50.0 0.30 (0.13-0.75) 0.2411 (0.04-1.47) 0.20" (0.04-0.97)
Vi-DT, 0.5 0.07** (0.04-1.12) 0.31 (0.06-1.52) 0.79 (0.28-2.24)
5.0 0.63*$ (0.30-1.30) 2.790 (0.65-12.0) 2.85ff (1 .09-7.46)
50.0 1.4011 (0.80-2.45) 2.65" (0.69-10.1) 3.00*** (1.39-6.46)SZU ET AL.
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FIGURE 3.
￿
Gel filtration profile
of Vi-CTx and its components,
Vi and CT, through S1000 Se-
phacryl equilibrated in 0.2 M
NaCl. (A) Conjugate. (0) refrac-
tive index, (0) OD 2,800 t\. (B)
Vi-cystamine. (*) refractive in-
dex, and CT, (A) OD 2,800 t1.
about sevenfold higher than those elicited by the Vi alone (p = 0.001). Each of
the three dosages of Vi-DTI elicited a booster response after the second injection .
No differences in the levels of antibodies elicited by the 5.0- and 50.0-tag doses
of Vi-DT, were observed; both of these doses were more immunogenic than 0.5
tig of this conjugate after the first injection only (p = 0 .001). Based upon these
data, the reports of Gaines et al. (41) and Landy (42), and our experience with
other conjugates (17, 19), all mice were immunized with 2 .5 ug of the Vi, alone
or as a component of a conjugate, in ensuing experiments.
Vi-Protein Conjugates with SPDP.
￿
An alternate conjugation procedure, which
covalently bound thiolated derivatives of the Vi- and the SPDP-derivatived
proteins, was studied in order to increase the yield and immunogenicity of the
Vi conjugates.
Introduction of thiol groups onto the Vi was attempted by forming amide
bonds between the amino groups of cysteamine (Fig. 1 b) and the carboxyls of
the Vi in the presence of EDAC. The yield of thiol added to the Vi by this
scheme was <1% wt/wt, probably because the SH groups of cysteamine were
oxidized. To avoid this possibility, cystamine was used, the thiols of which are
linked by disulphide bonds and are thus protected from oxidation (Fig. 1 c).
Using EDAC to catalyze amide bond formation, ^-6% wt/wt of cystamine was
bound to the Vi. After reduction of the disulphide bonds by DTT, the yield of
thiol esters was 0 .5-2% of the repeating monosaccharide. The freeze-dried
cystamine derivative of the Vi was stable at -20°C.
Physicochemical Characterization of the Vi Conjugates.
￿
The disulfide bonds of
the Vi-cystamine derivative were reduced with DTT before the conjugation
reaction. The molecular size of a representative conjugate, Vi-CTvJII (<O.1 kD)
was larger than that of the proteins (0 .64 kD) or the Vi (0.36 kD), as illustrated
by the gel filtration profile (Fig. 3). The composition of the thiolated Vi, the
SPDP-protein derivatives, and the conjugates used in these studies are listed in
Table II. The change in the molecular size of the intermediate and final products
of the conjugation reaction was further analyzed by SDS-PAGE (Fig. 4) . The
BSA-SPDP derivative exhibited a pattern similar to that of native BSA, demon-
strating that aggregation did not occur during the reaction with SPDP. The Vi-
BSA,v , as did all the Vi conjugates, failed to enter the gel, probably due to its1516
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TABLE II
Characterization of Vi-Protein Conjugates Prepared with N-Succinimidyl 3-(2-pyridylthio)
Propionate (SPDP)
* Percent of Vi recovered in conjugate .
FIGURE 4 . Polyacrylamide gel (7.5%) electrophoresis
pattern of BSA and its conjugate with Vi . (Lanes 1-4)
The migration pattern of samples reduced by 2-ME, (5
to 8) samples not treated by 2-ME . (2 and 5) Vi-BSA,v ,
(3 and 6) BSA-SPDP, (4 and 7) BSA, (1 and 8) protein
standards .
FIGURE 5 . Immunodiffusion pattern of Vi-BSA,v conju-
gate reacting with various antisera in 1% agarose gel . The
center well contained 15 Ml of Vi-BSA,v (0 .5 mg/ml) . Wells
1 and 4, Burro 260 anti-S . typhiTy2 antiserum ; wells 2 and
3, rabbit anti-BSA antiserum.
large size . Vi-BSA,v, reduced with 2-ME, exhibited a band similar to the native
BSA, indicating that the Vi was bound to this protein by a disulphide bond .
Antigenic Analysis .
￿
The Vi conjugates were analyzed byimmunodiffusion with
antisera to each of its components (Fig. 5) . Theanti-Vi and anti-BSA sera formed
Conjugate Yield* SH/Vi SPDP/protein Protein/Vi
wt/wt mol/mol wt/wt wt/wt
Vi-BSA,v 63.0 1 .2 17.0 0.078 0.7
Vi-CTv , 5.4 1 .0 5.4 0.019 0.4
Vi-CT, 18.0 0.5 4.5 0.016 1 .5
Vi-DTxv 14.9 0.5 5.0 0.024 1 .6
Vi-DTxx 16.8 0.4 3.8 0.018 1 .5
Vi-TTXXv 6.2 0.7 12.0 0.025 1 .4SZU ET AL.
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TABLE III
Serum Antibody Responses ofMice Injected with the Vi or Vi Conjugates with BSA, CT, DT or
TT Crosslinked with SPDP
Female, I6-20 g, BALB/c mice were injected subcutaneously with 0.2 ml containing 2.5 Ag Vi
or Vi conjugate 2 wk apart. Mice of each group were exsanguinated 10 dafter their last injection
and Vi antibodies were measured by RIA (59).
* Numbers indicate geometric mean (80% confidence limits).
t vs. 11,', *** M, of, III:p = 0.001; $ vs. 1: p = 0.002; tvs. II: p = 0.04; ** vs.': p = 0.0003; # vs.
t#: p = 0.003.
Adsorbed onto aluminiumhydroxide, 0.5 mg A12"/ml.
" Molecularsize of Vi reduced to ^x65,000 by ultrasonic irradiation (30).
a partial identity reaction with the conjugate indicating that the Vi and Vi-BSA
were covalently bound. The Vi antiserum reacted with the Vi and Vi-BSA,v with
a partial identity reaction; a spur of precipitation overrode the Vi line on to the
reaction of the antiserum with the Vi-BSAiv (not shown). Conjugates prepared
with DT, TT, and CT failed to react with their homologous antiprotein antisera
by immunodiffusion but did precipitate with these antisera by rocket immunoe-
lectrophoresis (not shown).
Residual Toxicity of Vi-CTx Conjugate.
￿
The toxicity of CT toxin was reduced
by its conjugation to Vi. A 10'-fold reduction was observed in the CHO cell
assay. The skin test in rabbits however, showed only a 1O'-fold reduction in
toxicity. Although injection with 0.5 ml of Vi-CTxct (one human dose) had no
effect on mice, injection of 5.0 ml i.p. of Vi-CTx resulted in the death of two
of three guinea pigs. This conjugate, therefore, did not pass the safety require-
ments of the Code of Federal Regulations (CFR 600:16).
Immunogenicity in Laboratory Mice.
￿
None of the preimmunization sera or sera
from mice injected with saline had detectable levels of Vi antibodies (Table 111).
All of the conjugates elicited higher levels of antibodies than the Vi alone (p =
0.001). The highest level of antibodies after the first injection were elicited by
the Vi-CT prepared from the Vi depolymerized by ultrasonic irradiation, but
these differences were not statistically significant. Booster responses after the
second injection, as defined by a fourfold or greater increase in the geometric
mean antibody levels, were observed in the animals injected with all the conju-
gates except the Vi-CT adsorbed. Vi-TTxxv also elicited an increase in antibodies
after the third injection. The levels in this group however, were similar to those
observed with the other conjugates after two injections. The poorest response
Immunogen n
1st injection
Antibody*
2nd injection 3rd injection
Pg/ml Wg/ml pg/ml
Vi 7 0.56$ (0.22-1.43) ND ND
Vi-BSA,v 7 2.861 (1 .25-6.53) ND ND
Vi-CTv, 4 1.351 (0.27-6.71) 4.53 (2.74-7.46) ND
Vi-CTx 10 2.12' (1 .29-3.47) 9.04** (4.84-16.9) 6.28# (1.98-19.9)
Vi-CTxufl 10 1.0111 (0.57-1.79) 1.16 (0.54-2.53) 0.87 (0.37-2.07)
Vi-CT UD" 10 2.94*** (1 .55-5.55) 4.23 (1 .75-10.2) ND
Vi-DTxv 10 2.57#$ (1 .27-5.17) 4.61 (2.49-8.52) ND
Vi-DTxx 10 1.76 (0.92-3.38) 1.26 (0.63-2.52) ND
Vi-TTxxv 9 2.56111 (1 .40-4.69) 3.15 (1 .71-5.80) 4.18 (2.74-6.36)1518
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TABLE IV
Serum Antibody Responses ofJuvenile Rhesus Monkeys Immunized with Vi, Vi Conjugated to
CT (Vi-CTx), or Pneumococcus Polysaccharide type 6B Conjugated to TT (Pn6B-TT)
Discussion
* Geometric mean (80% confidence limits). Measured by RIA (9). 1 vs.': p = 0.004,'vs. **: 0.02,
N
vs. **: p = 0.0003,' vs. t:p = 0.009, ** vs. 1: p=0.001. Monkeys were immunized subcutaneously
with 0.5 ml containing either 25 ug of Vi or 15 ug of Pn6B-TT at 3 wk intervals. The monkeys
were bled before each injectionand 3 wk afterthe last injection.
was elicited by Vi-CTxI, adsorbed; this preparation elicited the lowest levels of
antibodies after the first injection and there were no booster responses after the
second or third injections. There were differences in the immunogenicity of
conjugates prepared with the same components. The first injection of Vi-CTvIII
and Vi-CTxI, induced an ^-30-fold increase in CT antibodies, which also rose
fourfold after the second and third injections (data not shown). Vi-CTxI, elicited
higher levels ofCT antibodies, as well as Vi antibodies, than Vi-CTv1II.
Juvenile Rhesus.
￿
A single injection of Vi elicited Vi antibodies in five of the
six monkeys (p = 0.004) (Table IV). The levels of Vi antibodies declined in all
six monkeys after the second injection ofthe Vi. Seven ofeight monkeys injected
with Vi-CTxI, responded with a ^-20-fold increase in antibodies after the first
injection. The one nonresponding monkey had a preimmune level of 0.35 ug
antibody per milliliter. The second injection of the conjugate in this group
elicited about a threefold increase over that induced by the first injection of Vi-
CTxI, (p = 0.02) and -60 times the preimmunization level (p = 0.0003). The
monkey that did not respond to the first injection of Vi-CTxI, had a twofold
increase in antibodies after the second injection. No change in Vi antibodies was
observed after injection ofthe Pn6B-TT (control).
The pathogenic and protective roles of the Vi in typhoid fever have been
controversial (1, 2, 4, 7, 41-43). There are data that the Vi exerts the same
"shielding" effect upon S. typhi as do the CPS of the encapsulated bacterial
pathogens (2, 44-47). Now there is clinical evidence that antibodies elicited by
Vi confer immunity against typhoid fever (5, 6). The pathogenic and protective
roles of the Vi are therefore, similar to the CPS of other encapsulated bacterial
pathogens (47, 48).
The main, ifnot the sole, protective immuneresponse elicited by CPS is serum
antibodies. Both the seroconversion rates and postimmunization levels of anti-
bodies induced by CPS have beencorrelated with their protective actions. Serum
antibody responses induced by Vi in habitants of areas where typhoid fever is
endemic, where there is also a high rate of malnutrition and other acute and
chronic infections diseases, are less than optimal (2, 5, 10-12). Accordingly, we
Antibody*
Vaccine n
Pre-immune 1st injection 2nd injection
,ug/ml Ag/ml jug/ml
Vi 6 0.07 (0.05-0.10) 0.23$ (0.06-0.82) 0.07§ (0.05-0.09)
Vi-CTX 8 0.07° (0.03-0.19) 0.93' (0.24-3.55) 3.65** (0.72-18.5)
Pn6B-TT 8 0.08 (0.06-0.11) 0.10 (0.05-0.21) 0.10 (0.04-0.23)SZU ET AL.
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covalently bound the Vi to T-dependent proteins both to increase its immuno-
genicity and to confer upon it the properties ofT-dependency (19, 21, 49). This
synthesis offers several advantages, namely: (a) there is no crosslinking ofeither
component; (b) the reactions are conducted in aqueous solutions at neutral pH;
(c) the synthesis is applicable to other polysaccharides with carboxyl functions.
We have synthesized protein conjugates of Escherichia coli K93, pneumococcus
type 12 and Staphylococcus aureus type 8 by this scheme and are studying the
immunological properties of these conjugates (Fattom, A., W. Vann, S. C. Szu,
R. Schneerson, et al.); and (d) the carrier protein is only slightly modified and
can elicit antibodies to the native protein (25). The resultant conjugates elicited
higher levels ofantibodies than the Vi alone and induced a booster response in
weanling mice andjuvenile primates. Similar studies of Haemophilus influenzae
type b-protein conjugates were predictive of their enhanced antibody responses
in humans (15-17, 19-22). Whether Vi conjugates will elicit a higher serocon-
version rate and levels of antibodies in habitants of areas with high rates of
typhoid fever must be ascertained by clinical evaluation .
IgG Vi antibodies protected mice challenged with S. typhi(41, 50, 51). Indirect
evidence was provided that the Vi elicited IgG antibodies in humans (50). H.
influenzae type b-protein conjugates elicit IgG CPS antibodies (19-22). It is
likely therefore, that Vi conjugates will also elicit IgG antibodies. We plan to
evaluate the isotypes, IgG subclasses and the isoelectric pattern ofVi antibodies
elicited by Vi conjugates.
Convalescence from typhoid fever does not always confer immunity to S. typhi
(52, 53). Recent data may provide an explanation for this finding; convalescence
from typhoid fever does not always result in an elevation of Vi antibodies (31,
54-56). Tsang et al., reported that the Vi alone was a better immunogen in mice
than S. typhi strain 560Ty (56). Increasing evidence points to superior immuno-
genicity of CPS-protein conjugates compared with that of the homologous
bacteria in certain circumstances, namely: (a) conjugates of H. influenzae type b
elicit higher levels of CPS antibodies in infants and young children than do
systemic infections (15, 21); and (b) one to three injections of these conjugates
elicited higher levels of antibodies in mice than that elicited by the homologous
bacteria (Schneerson, R., andJ. B. Robbins, unpublished observations).
Unlike the CPS of many encapsulated bacterial pathogens, Vi induced serum
antibodies and conferred protection against lethal challenge with S. typhi in mice
(8). Heidelberger et al. (49) showed that reinjection ofseveral types of pneumo-
coccal CPS did not induce a booster response. Landy reported similar data with
the Vi in mice and humans (8, 42). We confirmed that reinjection ofVi did not
induce a booster effect in mice. In Rhesus monkeys, reinjection reduced the
levels ofVi antibodies. This could explain the findings of Gaines et al. (57) who
injected chimpanzees three times with Vi. The immunized chimpanzees had no
detectable Vi antibodies and were not protected against challenge with S. typhi.
The serum antibody responses elicited by conjugates prepared with SPDP
were higher than those prepared by direct binding with EDAC. An explanation
for this finding is that crosslinking reagents, such as SPDP, form conjugates with
a "spacer" between the two macromolecules. This property may enable a more1520
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effective interaction between the carrier protein and helper T lymphocytes (15,
18, 27, 58).
The higher levels of Vi antibodies elicited by the Vi-CT conjugates could be
explained by the adjuvant effect exerted by the residual activity (toxicity) ofthe
CT (20, 60, 61). The formation of a conjugate with the Vi reduced the toxicity
of the CT _1O3-104-fold . The resultant conjugate was lethal for the guinea pig,
but not mice, in the general safety test for bacterial vaccines described in the
Code ofFederal Regulations. This was probably due to the greater sensitivity of
guinea pigs to the lethal effects ofcholera toxin. We plan to conjugate the Vi to
the ,Q subunit of CT to avoid the problem of toxicity and yet induce serum
antibodies that may exert protective effects against other enterotoxigenic bacte-
rial pathogens (62).
Some of the primates in these experiments and healthy individuals in the
United States had preexisting serum Vi antibodies (19). Since S. typhi or S.
paratyphi C are rare in the United States, it is improbable that either of these
two pathogens were the stimulus for these Vi antibodies. One possible source
for the stimulus for these crossreacting antibodies could be the CPS of several
strains of S. aureus that have an aminogalacturonic acid moiety in their repeat
unit (62). The higher levels ofVi antibodies in young adults in countries where
typhoid fever is endemic are likely to have been stimulated by infection with S.
typhi.
S. typhi is an inhabitant ofand a pathogen for humans only; there are yet no
animal models or in vitro correlates of immunity that could be used to predict
the protective activities of Vi-conjugates. Only the mucin-enhanced lethal infec-
tion ofmice has been shown to correlate with the clinical effectiveness ofcellular
typhoid vaccines (7). The mouse protection model has been shown to be a
measure of Vi antibodies, whether actively induced or passively administered
(42). We have chosen to measure the Vi antibody response induced by the
conjugates in laboratory animals by RIA rather than this bioassay (9). Accord-
ingly, we plan to standardize the Vi conjugates by physicochemical and bioassays
as has been done for other conjugates, and to evaluate their clinical properties
ofsafety, immunogenicity, and then their protective actionsagainst typhoid fever
without the use ofanimal models (22).
Summary
The Vi has proven to be a protective antigen in two double masked, controlled
clinical trials in areas with high rates of typhoid fever (-I% per annum). In both
studies the protective efficacy of the Vi was ^-70%. ^-75% of subjects in these
areas responded with a fourfold or greater rise of serum Vi antibodies. In
contrast, the Vi elicited a fourfold or greater rise in 95-100% ofyoung adults
in France and the United States. Methods were devised, therefore, to synthesize
Vi-protein conjugates in order to both enhance the antibody response and confer
T-dependent properties to the Vi (and theoretically increase its protective action
in populations at high risk for typhoid fever). We settled on a method that used
the heterobifunctional crosslinking reagent, N-succinimidyl-3-(2-pyridyldithio)-
propionate (SPDP), to bind thiol derivatives ofthe Vi to proteins. This synthetic
scheme was reproducible, provided high yields ofVi-protein conjugates, and wasapplicable to several medically relevant proteins such as diphtheria and tetanus
toxoids. The resultant conjugates were more immunogenic in mice and juvenile
Rhesus monkeys than the Vi alone . In contrast to the T-independent properties
of the Vi, conjugates of this polysaccharide with several medically relevant
proteins induced booster responses in mice and in juvenile Rhesus monkeys.
Clinical studies with Vi-protein conjugates are planned. This scheme is also
applicable to synthesize protein conjugates with other polysaccharides that have
carboxyl functions.
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